Please try another search
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
David York Norton | 73 | 2018 | Independent Chairman & Lead Independent Director |
Thomas Lonngren | 74 | 2018 | Independent Non-Executive Director |
Annalisa Mary Jenkins | 59 | 2018 | Independent Non-Executive Director |
Kabir Nath | 60 | 2022 | CEO & Director |
Linda R. McGoldrick | 69 | 2020 | Independent Non Executive Director |
Kirk Rutter | - | - | Special Advisor of Patient Experience |
Daphne Karydas | 51 | 2023 | Independent Director |
Alan F. Schatzberg | 79 | - | Member of Scientific Advisory Network |
Paul Summergrad | - | - | Member of Scientific Advisory Network |
Thomas R. Insel | 71 | - | Member of Scientific Advisory Network |
Diego Pizzagalli | - | - | Member of Scientific Advisory Network |
Robert D. McQuade | 67 | 2020 | Independent Non Executive Director |
Gul Dolen | - | - | Member of Scientific Advisory Network |
John Rush | - | - | Member of Scientific Advisory Network |
Wayne Joseph Riley | 65 | 2021 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review